{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TIVICAY+%28DTG%29&page=3", "query": { "intervention": "TIVICAY (DTG)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TIVICAY+%28DTG%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TIVICAY+%28DTG%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T06:33:10.200Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07202546", "title": "A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4524184", "type": "DRUG" }, { "name": "Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets", "type": "DRUG" }, { "name": "Dolutegravir / Lamivudine (DTG/3TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2026-02-11", "completion_date": "2028-05-22", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 34, "location_summary": "Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07202546" }, { "nct_id": "NCT02582684", "title": "Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2015-12-08", "completion_date": "2017-09-26", "has_results": true, "last_update_posted_date": "2018-05-09", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 25, "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02582684" }, { "nct_id": "NCT03819114", "title": "Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Levonorgestrel (LNG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 122, "start_date": "2019-05-06", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2021-12-27", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 7, "location_summary": "Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819114" }, { "nct_id": "NCT02607930", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ABC/DTG/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "ABC/DTG/3TC Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2015-11-13", "completion_date": "2021-07-02", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607930" }, { "nct_id": "NCT05585307", "title": "Study of Novel Antiretrovirals in Participants With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bavtavirine", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Standard of Care (Substudy 01)", "type": "DRUG" }, { "name": "GS-1720", "type": "DRUG" }, { "name": "Standard of Care (Substudy 02)", "type": "DRUG" }, { "name": "GS-6212", "type": "DRUG" }, { "name": "Standard of Care (Substudy 03)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2022-10-26", "completion_date": "2024-03-18", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 38, "location_summary": "Long Beach, California • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585307" }, { "nct_id": "NCT00867152", "title": "GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Darunavir", "type": "DRUG" }, { "name": "Etravirine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2009-04", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-02-22", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867152" }, { "nct_id": "NCT01209065", "title": "GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Human Immunodeficiency Virus and Herpesviridae" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" }, { "name": "Fosamprenavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2010-09", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2017-01-19", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01209065" }, { "nct_id": "NCT07115368", "title": "Study of GS-1219 in Participants With HIV-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-1219", "type": "DRUG" }, { "name": "BVY", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2025-08-11", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115368" }, { "nct_id": "NCT00726336", "title": "GSK1349572 Drug Interaction With Tenofovir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "GSK1349572 and tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2008-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-10-15", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726336" }, { "nct_id": "NCT01910402", "title": "A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Dolutegravir/abacavir/lamivudine FDC", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/emtricitabine FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 499, "start_date": "2013-08-22", "completion_date": "2022-08-18", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-04T06:33:10.200Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01910402" } ] }